Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:NATCAPSUQ

NATURAL CAPSULES LIMITED

Healthcare › Pharmaceuticals & Biotechnology
₹136.50
at close · 28 Oct 2026
▼ 7.47 (-5.19%)

Latest filings

  1. Quarterly Compliance Certificate for Q2 FY26 Submitted · Compliance
  2. Trading window closure from October 1 ahead of Q2 results · Compliance
  3. EGM approves preferential allotment of shares and convertible warrants · Board & Shareholder Meetings
All filings ↓
Ask Nexa about NATURAL CAPSULES LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹191 Cr over the trailing twelve months.

Market Cap
₹142 Cr
P / E (TTM)
—
EV / EBITDA
86.4×
Div Yield
—
Growth
18.7%▲
Revenue 5y CAGR
PAT — · EBITDA -58.4%
Quality
4.4%·
ROCE (5y median)
ROE 2.4% (5y median) · margin 0.1%
Leverage
0.49·
Debt / Equity · low
Net debt ₹114 Cr
Revenue FY21→FY26
2.4×▲
Margin −21.9 pts
₹80 Cr → ₹187 Cr
Cash conversion
3.54×▲
Operating cash ÷ profit · 5 yrs
₹46 Cr on ₹13 Cr
Moves on a normal day
1.65%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/B#10/163
ROCE#167/183
ROE#155/166
Debt / Equity#136/166
EBITDA margin#134/165
Revenue growth#102/161
Profit growth#108/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 19% a year over 5 years
Over 5 years it reported ₹13 Cr of profit and ₹46 Cr of operating cash — 3.54×
Profit is converting into cash
Concerns
Erratic profits — up in only 2 of the last 5 years
Returns on capital 4.4% (5-year median)
#167 of 183 in Pharmaceuticals on the latest reported figures · down from 15.1% in FY21
Carries more debt than its peers — 0.49× equity
higher than 82% of its 166 Pharmaceuticals peers

Charts

How has the market priced it — with filings on the timeline?

NATCAPSUQ · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from NATURAL CAPSULES LIMITED's filed financials and exchange disclosures

What does NATURAL CAPSULES LIMITED do?

NATURAL CAPSULES LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol NATCAPSUQ.

Is NATURAL CAPSULES LIMITED profitable?

No. Over the trailing twelve months NATURAL CAPSULES LIMITED reported a net loss of ₹25 Cr on revenue of ₹191 Cr.

Does NATURAL CAPSULES LIMITED pay a dividend?

Not in the latest reported year — NATURAL CAPSULES LIMITED's dividend payout for FY26 was nil.

Is NATURAL CAPSULES LIMITED debt-free?

No. It reported borrowings of ₹114 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹114 Cr after cash. Debt stands at 0.49× equity. That is higher than 82% of its 166 Pharmaceuticals peers.

How much does the NATURAL CAPSULES LIMITED share price move in a day?

On a typical session NATURAL CAPSULES LIMITED moves 1.65% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

Where can I track NATURAL CAPSULES LIMITED's announcements?

Every NSE and BSE filing by NATURAL CAPSULES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.